Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes.
Scholze H, Stephenson RE, Reynolds R, Shah S, Puri R, Butler SD, Trujillo-Alonso V, Teater MR, van Besien H, Gibbs-Curtis D, Ueno H, Parvin S, Letai A, Mathew S, Singh A, Cesarman E, Melnick A, Giulino-Roth L.
Scholze H, et al. Among authors: melnick a.
Blood Adv. 2020 Oct 27;4(20):5226-5231. doi: 10.1182/bloodadvances.2020002580.
Blood Adv. 2020.
PMID: 33104794
Free PMC article.